Robust Bayesian sample size determination in clinical trials

Pierpaolo Brutti, Fulvio De Santis, Stefania Gubbiotti

Statistics in Medicine · 2008 · 69 citations · 23 references

Concepts

TL;DR

The article addresses sample size determination to ensure trial success. The study proposes a robust Bayesian sample size criterion that selects the minimal number of observations to achieve a sufficiently high predictive probability of trial success, mitigating sensitivity to prior assumptions. They adopt a Bayesian framework, defining success as a large posterior probability that the treatment effect exceeds a threshold, and extend it to a robust version by considering a class of plausible priors (ε‑contamination) and selecting sample sizes based on the predictive distribution of the lower bound of that posterior probability. The method is applied to determine sample sizes for a Phase III trial. © 2008 John Wiley & Sons, Ltd.

Abstract

Abstract This article deals with determination of a sample size that guarantees the success of a trial. We follow a Bayesian approach and we say an experiment is successful if it yields a large posterior probability that an unknown parameter of interest (an unknown treatment effect or an effects‐difference) is greater than a chosen threshold. In this context, a straightforward sample size criterion is to select the minimal number of observations so that the predictive probability of a successful trial is sufficiently large. In the paper we address the most typical criticism to Bayesian methods—their sensitivity to prior assumptions—by proposing a robust version of this sample size criterion. Specifically, instead of a single distribution, we consider a class of plausible priors for the parameter of interest. Robust sample sizes are then selected by looking at the predictive distribution of the lower bound of the posterior probability that the unknown parameter is greater than a chosen threshold. For their flexibility and mathematical tractability, we consider classes of ε‐contamination priors. As specific applications we consider sample size determination for a Phase III trial. Copyright © 2008 John Wiley & Sons, Ltd.

References

23